Z

Zevra Therapeutics Inc
NASDAQ:ZVRA

Watchlist Manager
Zevra Therapeutics Inc
NASDAQ:ZVRA
Watchlist
Price: 9.03 USD 4.27% Market Closed
Market Cap: 475.2m USD
Have any thoughts about
Zevra Therapeutics Inc?
Write Note

Zevra Therapeutics Inc
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zevra Therapeutics Inc
Accounts Receivables Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zevra Therapeutics Inc
NASDAQ:ZVRA
Accounts Receivables
$8.9m
CAGR 3-Years
68%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Accounts Receivables
$16.2B
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Accounts Receivables
$9.7B
CAGR 3-Years
7%
CAGR 5-Years
18%
CAGR 10-Years
18%
Pfizer Inc
NYSE:PFE
Accounts Receivables
$11.4B
CAGR 3-Years
-1%
CAGR 5-Years
4%
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Accounts Receivables
$11.4B
CAGR 3-Years
10%
CAGR 5-Years
6%
CAGR 10-Years
6%
Eli Lilly and Co
NYSE:LLY
Accounts Receivables
$10.3B
CAGR 3-Years
20%
CAGR 5-Years
13%
CAGR 10-Years
11%

See Also

What is Zevra Therapeutics Inc's Accounts Receivables?
Accounts Receivables
8.9m USD

Based on the financial report for Jun 30, 2024, Zevra Therapeutics Inc's Accounts Receivables amounts to 8.9m USD.

What is Zevra Therapeutics Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 3Y
68%

Over the last year, the Accounts Receivables growth was -36%. The average annual Accounts Receivables growth rates for Zevra Therapeutics Inc have been 68% over the past three years .

Back to Top